3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1
3
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Status
Recruiting
3
Completed
3
Withdrawn
1
Terminated
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
1
Neoplasm Metastasis
1
Interventions
Cyclophosphamide
119
Specimen Handling
104
pembrolizumab
102
Magnetic Resonance Spectroscopy
96
fludarabine
92
Biopsy
79
Injections
53
Nivolumab
41
venetoclax
40
Bevacizumab
40
Fluorouracil
38
Paclitaxel
37
Cisplatin
36
Cetuximab
35
Carboplatin
35
Gemcitabine
31
fludarabine phosphate
30
Radiotherapy
30
Oxaliplatin
30
Leucovorin
28
Immunotherapy, Adoptive
25
Drug Therapy
25
Ipilimumab
24
Azacitidine
23
Irinotecan
21
130-nm albumin-bound paclitaxel
21
tislelizumab
20
Temozolomide
20
Radiation
20
atezolizumab
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
Recruiting
×
tucatinib
×
Clear all
NCT06239467
2025-09-09
PIKture-01
OnKure, Inc.
Phase 1
Recruiting
200 enrolled
NCT05868226
2025-04-04
PRE-I-SPY-PI
QuantumLeap Healthcare Collaborative
Phase 1
Recruiting
124 enrolled
NCT06162559
2024-01-11
TRAIN-4
The Netherlands Cancer Institute
Phase 1
Recruiting
30 enrolled